There is no cure for psoriasis at this time, and we found no report of one in 2025 or 2026. But that short answer needs context. This article covers what happens when people stop treatment, why immune memory in the skin may matter, how far gene editing research has got, and what you can do now.
Why there is no cure yet
The National Psoriasis Foundation says it does not claim a cure exists, and describes its research initiatives as hoping to lead to one.[1] Psoriasis is immune-mediated. The NPF describes biologic medicines as targeting specific parts of the immune system.[2] Genes play a role too. A 2018 review calls HLA-C*06:02 the main psoriasis risk gene, with odds ratios of about 3 to 10 in several populations. It adds that more than 60 other common variants have been found, and that psoriasis arises from the interaction of genes with environmental, infectious and lifestyle factors. It names Streptococcus pyogenes infection as a major infectious trigger.[3] Because many genes and exposures are involved, no cure has been found.
What happens when treatment stops
Two studies of people who stopped biologic medicines after their skin cleared show how often psoriasis returns. They define relapse differently, so their numbers cannot be compared directly.
After stopping IL-23 biologics, 90.5% relapsed (38 of 42). The median time off drug among those who relapsed was 104 days, and 76.2% relapsed within a year. Relapse meant needing any systemic treatment or phototherapy. It was a small single-center study, and the authors note the relapse criteria were less strict than in pivotal trials.[4]
Over 12 years, time to relapse after stopping was longest for IL-23 inhibitors, then IL-12/23, IL-17 and TNF inhibitors. The more times people had stopped a biologic before, the sooner relapse came. The authors say repeated stopping should be weighed carefully.[5]
These studies show that psoriasis usually returns after treatment stops, though the time varies. They do not show that any treatment is a cure. Some people stay clear for longer, so the effect on you is a conversation for your doctor.
Do not stop treatment on your own. Never stop or change a prescribed medication without talking to your doctor.
Where the research is heading
Immune memory in the skin
Psoriasis often returns in the same spots. A 2017 study from Brigham and Women's Hospital, read as a news release, found that skin where psoriasis had cleared still held IL-17-producing T cells with receptor sequences found only in people with psoriasis. The team suggested these tissue-resident memory T cells may drive recurrence, and that most treatments suppress them rather than remove them. It was a proposal: the release did not report sample sizes, and no therapy to remove these cells had been developed or tested.[6]
A 2024 systematic review reaches a similar place. It describes recurrence at previously affected sites as a major challenge and proposes that localized immune memory persists in cleared skin. It reports mixed evidence on whether current drugs reduce these cells, notes that many included studies were small (5 to 20 patients), and describes treatments aimed at these cells as early-stage. Two of its authors are affiliated with a drug maker.[7]
Gene editing
Gene editing is the most direct idea for a cure, but we found work only in mice and in lab cells. A 2025 study used CRISPR in lipid nanoparticles, applied to mouse ears, to switch off two inflammation-related genes. Skin inflammation fell in the mouse model, with three mice per group. The authors say off-target editing, immune reactions to the delivery system and long-term effects are still concerns, and that testing in human skin models is a future step.[8] A 2026 lab screen, read as a news summary, used AI-guided CRISPR to look for new targets in human skin cells and tested two drugs in mice, with no human efficacy data.[9] We found no human trial of gene editing in psoriasis.
The gut, AI and new medicines
A 2024 analysis of 7 probiotic trials (400 people) did not find a significant effect on the main outcome, a 75% PASI improvement.[10] For the full picture, see The Link Between Gut Health and Psoriasis. For new approvals, a pill under FDA review and what AI can and cannot do yet, see What's New in Psoriasis Research: The Latest Advances.
What this means now
Research toward a cure is real but early, and we found nothing that changes what people can do today. A dermatologist can help match a treatment to the type and severity of your psoriasis, check whether you also have joint symptoms, and plan what to do if symptoms return.
Practical tip. Keep a simple record of flares, treatments and anything that seems to change them, and bring it to appointments. This is general good practice, not a research finding. For treatment options and planning, see Creating a Psoriasis Treatment Plan That Works for You.
Nopsor and your routine
Coal tar is an over-the-counter ingredient that helps temporarily relieve the itching, scaling, flaking, redness and irritation associated with psoriasis. Nopsor Body Wash & Shampoo has coal tar (2.2%) and salicylic acid as key ingredients, and Nopsor Deep Moisturizing Ointment has coal tar, salicylic acid and an 8-plant herbal blend. In the nightly routine, leave the wash on for about 3 minutes before rinsing, as the label directs, then apply the Ointment. Begin with a small area the first few nights, and stop and ask a doctor if irritation is severe or your skin gets worse. Nopsor is for the skin symptoms of psoriasis. It is not for joint pain. Coal tar can make skin more sensitive to the sun for up to 24 hours, so use caution with sun exposure and use sunscreen on treated areas. For directions, see The Nightly Routine: How to Apply Nopsor for Best Results. Never stop or change a prescribed medication without talking to your doctor.
Nopsor is not for children under 12 unless directed by a doctor.
References
- National Psoriasis Foundation. Working toward a cure. psoriasis.org (an advocacy-group research page; no date or author shown). psoriasis.org
- National Psoriasis Foundation. Biologics. Last updated March 24, 2025 (no reviewer named). psoriasis.org
- Prinz JC. Human leukocyte antigen-class I alleles and the autoreactive T cell response in psoriasis pathogenesis. Frontiers in Immunology, 2018;9 (mini review; we read most of the text). frontiersin.org
- Hsieh CY, Hsu FLT, Tsai TF. Comparison of drug-free remission after the end of phase III trials of three different anti-IL-23 inhibitors in psoriasis. Dermatology and Therapy, 2024 (single center, 42 people; authors disclose payments from drug makers). springer.com
- Huang YH, Hung SJ, Lee CN, et al. Predicting the time to relapse following withdrawal from different biologics in patients with psoriasis who responded to therapy: a 12-year multicenter cohort study. American Journal of Clinical Dermatology, 2024;25(6):997–1008 (abstract page only). tcu.elsevierpure.com
- EurekAlert. News release on why psoriasis lesions return in the same spots. September 28, 2017 (Brigham and Women's Hospital and Rockefeller University; summary of Matos TR, et al., Journal of Clinical Investigation, 2017; the paper was not opened). eurekalert.org
- Lobão B, Lourenço D, Giga A, Mendes-Bastos P. From PsO to PsA: the role of TRM and Tregs in psoriatic disease, a systematic review of the literature. Frontiers in Medicine, 2024;11 (we read the first part of the text; two authors are affiliated with Janssen Portugal). frontiersin.org
- Xu G, Ma G, Sun J, Yu X, Sun J, Gao B. Comprehensive analysis of pyroptosis-related genes in psoriasis and targeted gene editing of CASP1 and CASP5 using lipid nanoparticles to alleviate skin inflammation. Frontiers in Bioengineering and Biotechnology, 2025;13 (mouse study). frontiersin.org
- ReachMD. AI-guided CRISPR finds new psoriasis targets in keratinocytes. July 27, 2026 (news summary of a Nature Communications paper by Zhao et al.; the paper was not opened; lab and mouse work). reachmd.com
- Zhu Y, Xu F, Chen H, Zheng Q. The efficacy and safety of probiotics in the adjuvant treatment of psoriasis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine, 2024;11:1448626. pmc.ncbi.nlm.nih.gov
This article is for educational purposes only and does not replace medical advice. Only a doctor can diagnose a skin condition and recommend treatment.